Clinical Trials, Phase III as Topic
"Clinical Trials, Phase III as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
MeSH Number(s)
E05.318.760.535.220
E05.337.250.220
N05.715.360.775.235.220
N06.850.520.450.535.220
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase III as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase III as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase III as Topic" by people in Harvard Catalyst Profiles by year, and whether "Clinical Trials, Phase III as Topic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 1 | 2 |
1995 | 1 | 0 | 1 |
1996 | 1 | 1 | 2 |
1997 | 1 | 3 | 4 |
1998 | 1 | 2 | 3 |
1999 | 1 | 2 | 3 |
2000 | 0 | 3 | 3 |
2001 | 0 | 9 | 9 |
2002 | 3 | 5 | 8 |
2003 | 3 | 4 | 7 |
2004 | 4 | 7 | 11 |
2005 | 2 | 14 | 16 |
2006 | 3 | 10 | 13 |
2007 | 0 | 12 | 12 |
2008 | 5 | 23 | 28 |
2009 | 4 | 15 | 19 |
2010 | 4 | 17 | 21 |
2011 | 2 | 24 | 26 |
2012 | 6 | 20 | 26 |
2013 | 10 | 18 | 28 |
2014 | 8 | 16 | 24 |
2015 | 0 | 17 | 17 |
2016 | 5 | 23 | 28 |
2017 | 5 | 29 | 34 |
2018 | 9 | 33 | 42 |
2019 | 5 | 35 | 40 |
2020 | 1 | 36 | 37 |
2021 | 4 | 31 | 35 |
2022 | 1 | 22 | 23 |
2023 | 0 | 17 | 17 |
2024 | 0 | 3 | 3 |
Below are the most recent publications written about "Clinical Trials, Phase III as Topic" by people in Profiles.
-
Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling? Neuro Oncol. 2024 02 02; 26(2):211-225.
-
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00. Eur J Cancer. 2024 Mar; 200:113535.
-
Optimizing the use of ketamine to reduce chronic postsurgical pain in women undergoing mastectomy for oncologic indication: study protocol for the KALPAS multicenter randomized controlled trial. Trials. 2024 Jan 19; 25(1):67.
-
The Interaction of Acute Kidney Injury with Resuscitation Strategy in Sepsis: A Secondary Analysis of a Multicenter, Phase 3, Randomized Clinical Trial (CLOVERS). Am J Respir Crit Care Med. 2023 Dec 15; 208(12):1335-1338.
-
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial. Trials. 2023 Nov 30; 24(1):773.
-
Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol. BMJ Open. 2023 11 29; 13(11):e077427.
-
Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2023 12 01; 77(6):760-768.
-
GRECCAR 14 - a multicentric, randomized, phase II-III study evaluating the tailored management of locally advanced rectal carcinoma after a favourable response to induction chemotherapy: Study protocol. Colorectal Dis. 2023 10; 25(10):2078-2086.
-
Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review. JAMA Cardiol. 2023 09 01; 8(9):879-887.
-
Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab. Osteoarthritis Cartilage. 2023 Dec; 31(12):1612-1626.